Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSPB1 | P04792 | 3/20 | 0.45 |
| ▸ | MEN1 | O00255 | 5/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.44 |
| ▸ | MAPT | P10636 | 4/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.43 |
| ▸ | ZAP70 | P43403 | 1/20 | 0.42 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | AHR | P35869 | 1/20 | 0.39 |
| ▸ | MMP1 | P03956 | 1/20 | 0.39 |
| ▸ | MMP2 | P08253 | 1/20 | 0.39 |
| ▸ | MMP9 | P14780 | 1/20 | 0.39 |
| ▸ | MMP8 | P22894 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16010165 | 0.84 | MEN1 (0.58) | HSPB1MEN1KMT2AMAPTALDH1A1 | |
| SCHEMBL23779899 | 0.81 | MAPT (0.53) | HSPB1MEN1KMT2AMAPTALDH1A1 | |
| SCHEMBL21652751 | 0.81 | MAPT (0.53) | HSPB1MEN1KMT2AMAPTALDH1A1 | |
| SCHEMBL30194046 | 0.76 | ATM (0.43) | MEN1KMT2AMAPTALDH1A1LMNA | |
| SCHEMBL28509223 | 0.76 | ATM (0.43) | MEN1KMT2AMAPTALDH1A1LMNA | |
| SCHEMBL15999439 | 0.75 | MEN1 (0.56) | MEN1KMT2AMAPTALDH1A1LMNA | |
| SCHEMBL16009506 | 0.73 | AHR (0.52) | MEN1KMT2AMAPTALDH1A1LMNA | |
| SCHEMBL16049221 | 0.73 | HSPB1 (0.63) | HSPB1MAPTHTTTDP1GAA | |
| SCHEMBL14909529 | 0.72 | ALDH1A1 (0.43) | MAPTALDH1A1LMNAHTTTDP1 | |
| SCHEMBL23925574 | 0.72 | ALDH1A1 (0.43) | MEN1KMT2AMAPTALDH1A1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210070756-A1 | TETRACYCLIC BROMODOMAIN INHIBITORS | ABBVIE INC (US) | 2021-03-11 | — | — | US | disclosed |
| US-20200291027-A1 | TETRACYCLIC BROMODOMAIN INHIBITORS | ABBVIE INC (US) | 2020-09-17 | — | — | US | disclosed |
| EP-3539962-A1 | TETRACYCLIC BROMODOMAIN INHIBITORS | AbbVie Inc. (US) | 2019-09-18 | — | — | EP | disclosed |
| EP-2970330-B1 | TETRACYCLIC BROMODOMAIN INHIBITORS | ABBVIE INC (US) | 2019-04-17 | — | — | EP | disclosed |
| EP-2970285-B1 | FUSED TETRACYCLIC BROMODOMAIN INHIBITORS | ABBVIE INC (US) | 2019-04-17 | — | — | EP | disclosed |
| US-20180298003-A1 | TETRACYCLIC BROMODOMAIN INHIBITORS | ABBVIE INC (US) | 2018-10-18 | — | — | US | disclosed |
| US-10035800-B2 | Substituted 1,4,10-triazadibenzo[cd,f]azulenes, substituted 1,4,5,10-tetraazadibenzo[cd,f]azulenes and substituted 1,4,5,7,10-pentaazadibenzo[cd,f]azulenes as bromodomain inhibitors | ABBVIE INC. (US) | 2018-07-31 | — | — | US | disclosed |
| US-20160039821-A1 | TETRACYCLIC BROMODOMAIN INHIBITORS | ABBVIE INC. | 2016-02-11 | — | — | US | disclosed |
| EP-2970285-A1 | FUSED TETRACYCLIC BROMODOMAIN INHIBITORS | AbbVie Inc. (US) | 2016-01-20 | — | — | EP | disclosed |
| US-20150150884-A1 | BROMODOMAIN INHIBITORS | ABBVIE INC. | 2015-06-04 | — | — | US | disclosed |
| US-8980879-B2 | Bromodomain inhibitors | ABBVIE INC. (US) | 2015-03-17 | — | — | US | disclosed |
| WO-2014164780-A1 | FUSED TETRACYCLIC BROMODOMAIN INHIBITORS | ABBVIE INC. (US) | 2014-10-09 | — | — | WO | disclosed |
| US-20140256710-A1 | BROMODOMAIN INHIBITORS | ABBVIE INC. | 2014-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10035800-B2 | Substituted 1,4,10-triazadibenzo[cd,f]azulenes, substituted 1,4,5,10-tetraazadibenzo[cd,f]azulenes and substituted 1,4,5,7,10-pentaazadibenzo[cd,f]azulenes as bromodomain inhibitors | BRD1, BRD3, BRD4 | HSPB1 2010/4885MEN1 1300/4885KMT2A 2376/4885 |
| US-20180298003-A1 | TETRACYCLIC BROMODOMAIN INHIBITORS | BRD3, BRD4, BRD1 | HSPB1 3072/4885MEN1 792/4885KMT2A 577/4885 |
| US-20200291027-A1 | TETRACYCLIC BROMODOMAIN INHIBITORS | BRD3, BRD4, BRD1 | HSPB1 3072/4885MEN1 792/4885KMT2A 577/4885 |
| US-20210070756-A1 | TETRACYCLIC BROMODOMAIN INHIBITORS | BRD3, BRD4, BRD1 | HSPB1 3072/4885MEN1 792/4885KMT2A 577/4885 |
| US-20150150884-A1 | BROMODOMAIN INHIBITORS | BRD4, BRD3, BRD1 | HSPB1 2774/4885MEN1 594/4885KMT2A 350/4885 |
| US-20160039821-A1 | TETRACYCLIC BROMODOMAIN INHIBITORS | BRD3, BRD4, BRD1 | HSPB1 3184/4885MEN1 736/4885KMT2A 611/4885 |
| US-20140256710-A1 | BROMODOMAIN INHIBITORS | BRD4, BRD3, BRD1 | HSPB1 2774/4885MEN1 594/4885KMT2A 350/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.